Pharma IQ takes a look at some of the industry’s most prestigious movers and shakers causing ripples in the market over the last few months.
In order to examine the therapy which has been labelled as a game changing addition to oncology, earlier this month industry stakeholders met to explore the evidenced potential of immune checkpoint modulation therapies. The two day conference also saw attendees discuss and formulate tactics to scale the roadblocks encountered by the therapy.
Biomarkers are an essential part of such a translational effort and are critical to understanding human disease. Human biospecimens can provide a bridge between the early discovery and molecular mechanism of the disease and the clinical utility. Commonly, human biospecimens are used to:
The balanced scorecard was first developed as a way for companies and organizations to more accurately measure their own performances. Today, these scorecards have evolved into vital tools for biopharmaceutical organizations to plan, measure, and manage their business strategies.
There are questions virtually everyone in our industry asks when the topic of commercialization inevitably comes up: What is new in molecule commercialization? How do I beat my closest competitor? When do I initiate commercial activities? What can I do based on promotional regulations?
The first quarter of 2016 hosted plenty of activity from the pharma and cold chain industries. This was seen in the form of patent challenges, landmark agreements, extreme market reactions as well as a nationwide medicine ban for hundreds of products. Read on for this quarter’s highlights from Pharma IQ
Pharma IQ takes a look at which pharmaceutical products emerge at the front of the pack on the global healthcare industry.
The global healthcare CRO market has been forecasted to reach US$45 billion by 2022, according to new research. (2) In terms of market shares, the geos rank as follows: North America, Europe, Asia Pacific, with China and India expected to see dramatic growth within this period. In light of this growing market, the Pharma IQ community was invited to rate which firms would appear in their list of top 10 CROs.
In 2015, the pharma and biotech industry was diagnosed with what was coined as merger fever. Industry analysts state that the first half of 2015 soared past 2014’s grand total of $162 billion, with the total value of pharma M&As in the first two quarters of 2015 sitting at $221 billion.